welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
active, not recruiting

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)

key information

study id #: NCT03406780

condition: Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn

status: active, not recruiting

purpose:

HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.

intervention: CAP-1002, Placebo

mechanism of action: Cardiac progenitor cells to promote cellular regeneration

results: https://clinicaltrials.gov/ct2/show/results/NCT03406780

last updated: May 06, 2019